{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+II+Adult+Liver+Cancer&page=8", "query": { "condition": "Stage II Adult Liver Cancer", "page": 8 }, "page_size": 10 }, "pagination": { "page": 8, "page_size": 10, "total_count": 234, "total_pages": 24, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+II+Adult+Liver+Cancer&page=9&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+II+Adult+Liver+Cancer&page=7&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-12T04:22:47.322Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00096083", "title": "Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "isolated perfusion", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Delcath Systems Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 56, "start_date": "2004-09", "completion_date": "2012-08", "has_results": false, "last_update_posted_date": "2013-10-23", "last_synced_at": "2026-10-12T04:22:47.322Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00096083" }, { "nct_id": "NCT02279719", "title": "A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hepatocellular Carcinoma" ], "interventions": [ { "name": "BBI608", "type": "DRUG" }, { "name": "BBI503", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sumitomo Pharma America, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 97, "start_date": "2014-12", "completion_date": "2019-10", "has_results": true, "last_update_posted_date": "2023-11-15", "last_synced_at": "2026-10-12T04:22:47.322Z", "location_count": 29, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Coronado, California + 25 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Coronado", "state": "California" }, { "city": "Encinitas", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02279719" }, { "nct_id": "NCT05194293", "title": "Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage IB Hepatocellular Carcinoma AJCC v8", "Stage II Hepatocellular Carcinoma AJCC v8", "Stage III Hepatocellular Carcinoma AJCC v8", "Stage IIIA Hepatocellular Carcinoma AJCC v8" ], "interventions": [ { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Regorafenib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Academic and Community Cancer Research United", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2023-07-01", "completion_date": "2028-12-05", "has_results": true, "last_update_posted_date": "2026-07-20", "last_synced_at": "2026-10-12T04:22:47.322Z", "location_count": 3, "location_summary": "Birmingham, Alabama • Atlanta, Georgia • Milwaukee, Wisconsin", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT05194293" }, { "nct_id": "NCT00058487", "title": "Epirubicin and Thalidomide in Treating Patients With Liver Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Liver Cancer" ], "interventions": [ { "name": "epirubicin hydrochloride", "type": "DRUG" }, { "name": "thalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2001-12", "completion_date": "2007-01", "has_results": false, "last_update_posted_date": "2013-07-18", "last_synced_at": "2026-10-12T04:22:47.322Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00058487" }, { "nct_id": "NCT03107416", "title": "Delivering a Diuretic Into the Liver Artery Followed by Plugging up the Artery to Starve Out Liver Cancer Cells", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Unresectable Hepatocellular Carcinoma" ], "interventions": [ { "name": "Hepatic artery embolization (HAE)", "type": "PROCEDURE" }, { "name": "Bumetanide", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2017-04-05", "completion_date": "2027-04-05", "has_results": false, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-10-12T04:22:47.322Z", "location_count": 5, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 2 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Harrison", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03107416" }, { "nct_id": "NCT02940496", "title": "Pembrolizumab (MK-3475) in Hepatocellular Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "BCLC Stage B Hepatocellular Carcinoma", "BCLC Stage C Hepatocellular Carcinoma", "Hepatitis C Infection", "Refractory Liver Carcinoma", "Stage III Hepatocellular Carcinoma AJCC v7", "Stage IIIA Hepatocellular Carcinoma AJCC v7", "Stage IIIB Hepatocellular Carcinoma AJCC v7", "Stage IIIC Hepatocellular Carcinoma AJCC v7", "Stage IV Hepatocellular Carcinoma AJCC v7", "Stage IVA Hepatocellular Carcinoma AJCC v7", "Stage IVB Hepatocellular Carcinoma AJCC v7" ], "interventions": [ { "name": "Elbasvir/Grazoprevir", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2016-12-09", "completion_date": "2023-08-09", "has_results": true, "last_update_posted_date": "2025-07-15", "last_synced_at": "2026-10-12T04:22:47.322Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02940496" }, { "nct_id": "NCT00608361", "title": "Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Acute Lymphoblastic Leukemia in Remission", "Adult B Acute Lymphoblastic Leukemia", "Adult Hepatocellular Carcinoma", "Adult Nasal Type Extranodal NK/T-Cell Lymphoma", "Adult Solid Neoplasm", "Adult T Acute Lymphoblastic Leukemia", "Advanced Adult Hepatocellular Carcinoma", "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-Cell Lymphoma", "Chronic Lymphocytic Leukemia", "Cutaneous B-Cell Non-Hodgkin Lymphoma", "Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue", "Hepatosplenic T-Cell Lymphoma", "Intraocular Lymphoma", "Localized Non-Resectable Adult Liver Carcinoma", "Localized Resectable Adult Liver Carcinoma", "Lymphomatous Involvement of Non-Cutaneous Extranodal Site", "Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma", "Nodal Marginal Zone Lymphoma", "Progressive Hairy Cell Leukemia Initial Treatment", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Lymphoma", "Recurrent Adult Liver Carcinoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Adult T-Cell Leukemia/Lymphoma", "Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides and Sezary Syndrome", "Recurrent Small Lymphocytic Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Hairy Cell Leukemia", "Small Intestinal Lymphoma", "Splenic Marginal Zone Lymphoma", "Stage II Small Lymphocytic Lymphoma", "Stage III Adult Burkitt Lymphoma", "Stage III Adult Diffuse Large Cell Lymphoma", "Stage III Adult Diffuse Mixed Cell Lymphoma", "Stage III Adult Diffuse Small Cleaved Cell Lymphoma", "Stage III Adult Hodgkin Lymphoma", "Stage III Adult Immunoblastic Lymphoma", "Stage III Adult Lymphoblastic Lymphoma", "Stage III Adult T-Cell Leukemia/Lymphoma", "Stage III Chronic Lymphocytic Leukemia", "Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma", "Stage III Grade 1 Follicular Lymphoma", "Stage III Grade 2 Follicular Lymphoma", "Stage III Grade 3 Follicular Lymphoma", "Stage III Mantle Cell Lymphoma", "Stage III Marginal Zone Lymphoma", "Stage III Small Lymphocytic Lymphoma", "Stage IIIA Mycosis Fungoides and Sezary Syndrome", "Stage IIIB Mycosis Fungoides and Sezary Syndrome", "Stage IV Adult Burkitt Lymphoma", "Stage IV Adult Diffuse Large Cell Lymphoma", "Stage IV Adult Diffuse Mixed Cell Lymphoma", "Stage IV Adult Diffuse Small Cleaved Cell Lymphoma", "Stage IV Adult Hodgkin Lymphoma", "Stage IV Adult Immunoblastic Lymphoma", "Stage IV Adult Lymphoblastic Lymphoma", "Stage IV Adult T-Cell Leukemia/Lymphoma", "Stage IV Chronic Lymphocytic Leukemia", "Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma", "Stage IV Grade 1 Follicular Lymphoma", "Stage IV Grade 2 Follicular Lymphoma", "Stage IV Grade 3 Follicular Lymphoma", "Stage IV Mantle Cell Lymphoma", "Stage IV Marginal Zone Lymphoma", "Stage IV Small Lymphocytic Lymphoma", "Stage IVA Mycosis Fungoides and Sezary Syndrome", "Stage IVB Mycosis Fungoides and Sezary Syndrome", "T-Cell Large Granular Lymphocyte Leukemia", "Testicular Lymphoma", "Untreated Adult Acute Lymphoblastic Leukemia", "Untreated Hairy Cell Leukemia", "Waldenstrom Macroglobulinemia" ], "interventions": [ { "name": "Dasatinib", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2008-10", "completion_date": "2014-08", "has_results": false, "last_update_posted_date": "2015-07-02", "last_synced_at": "2026-10-12T04:22:47.322Z", "location_count": 23, "location_summary": "Duarte, California • Los Angeles, California • Sacramento, California + 14 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Hays", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00608361" }, { "nct_id": "NCT04805788", "title": "Stereotactic Body Proton Radiotherapy for the Treatment of Liver Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Hepatocellular Carcinoma", "Stage I Hepatocellular Carcinoma AJCC v8", "Stage II Hepatocellular Carcinoma AJCC v8", "Stage III Hepatocellular Carcinoma AJCC v8" ], "interventions": [ { "name": "Proton Stereotactic Body Radiation Therapy", "type": "RADIATION" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "RADIATION", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2021-08-24", "completion_date": "2025-01-28", "has_results": false, "last_update_posted_date": "2025-12-31", "last_synced_at": "2026-10-12T04:22:47.322Z", "location_count": 2, "location_summary": "Scottsdale, Arizona • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04805788" }, { "nct_id": "NCT03422679", "title": "Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer", "Colorectal Cancer", "Adenoid Cystic Carcinoma", "Non-hodgkin Lymphoma", "Glomus Tumor, Malignant", "Hepatocellular Carcinoma", "Osteosarcoma", "T-ALL" ], "interventions": [ { "name": "CB-103", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cellestia Biotech AG", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 79, "start_date": "2017-12-05", "completion_date": "2022-11-11", "has_results": true, "last_update_posted_date": "2024-01-16", "last_synced_at": "2026-10-12T04:22:47.322Z", "location_count": 3, "location_summary": "Santa Monica, California • Boston, Massachusetts • Houston, Texas", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03422679" }, { "nct_id": "NCT06789848", "title": "Ligufalimab and Cadonilimab in Advanced Liver Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Hepatocellular Carcinoma", "Refractory Hepatocellular Carcinoma", "Biliary Tract Cancer" ], "interventions": [ { "name": "Ligufalimab", "type": "DRUG" }, { "name": "Cadonilimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2025-02-18", "completion_date": "2030-05-31", "has_results": false, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-10-12T04:22:47.322Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06789848" } ] }